## Dirk Vordermark

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1828492/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncology, The, 2022, 23, 125-137.	10.7	59
2	Shift of radiotherapy use during the first wave of the COVID-19 pandemic? An analysis of German inpatient data. Strahlentherapie Und Onkologie, 2022, 198, 334-345.	2.0	8
3	Development and Evaluation of a Multimodal Supportive Intervention for Promoting Physical Function in Older Patients with Cancer. Cancers, 2022, 14, 2599.	3.7	3
4	Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells. Chemico-Biological Interactions, 2021, 333, 109326.	4.0	15
5	Pediatric classical Hodgkin lymphoma. Pediatric Blood and Cancer, 2021, 68, e28562.	1.5	12
6	Decision Making in Geriatric Oncology: Supported Versus Assisted Decision Making. Journal of Clinical Oncology, 2021, 39, JCO.21.01643.	1.6	1
7	MSBA-S – A pentacyclic sulfamate as a new option for radiotherapy of human breast cancer cells. European Journal of Medicinal Chemistry, 2021, 224, 113721.	5.5	9
8	Quality of life in patients with limited (1–3) brain metastases undergoing stereotactic or whole brain radiotherapy. Strahlentherapie Und Onkologie, 2020, 196, 48-57.	2.0	21
9	The Role of Postoperative Radiotherapy for Carcinosarcoma of the Uterus. Cancers, 2020, 12, 3573.	3.7	6
10	Effect of Radiotherapy in Addition to Surgery in Early Stage Endometrial Cancer: A Population-Based Study. Cancers, 2020, 12, 3814.	3.7	3
11	Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups. Radiation Oncology, 2020, 15, 140.	2.7	25
12	Benefit from surgery with additional radiotherapy in N1 head and neck cancer at the time of IMRT: A population-based study on recent developments. PLoS ONE, 2020, 15, e0229266.	2.5	7
13	Evaluation of machine learning models for automatic detection of DNA double strand breaks after irradiation using a γH2AX foci assay. PLoS ONE, 2020, 15, e0229620.	2.5	10
14	Lung Cancer Attributed Mortality Among 316,336 Early Stage Breast Cancer Cases Treated by Radiotherapy and/or Chemotherapy, 2000–2015: Evidence From the SEER Database. Frontiers in Oncology, 2020, 10, 602397.	2.8	1
15	<p>Development and Validation of an Information Leaflet on Oral Care for Irradiated Patients</p> . Patient Preference and Adherence, 2020, Volume 14, 1791-1799.	1.8	6
16	Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms. Cancers, 2019, 11, 889.	3.7	17
17	Prediction of regulatory targets of alternative isoforms of the epidermal growth factor receptor in a glioblastoma cell line. BMC Bioinformatics, 2019, 20, 434.	2.6	6
18	Causes and Consequences of A Glutamine Induced Normoxic HIF1 Activity for the Tumor Metabolism. International Journal of Molecular Sciences, 2019, 20, 4742.	4.1	19

#	Article	IF	CITATIONS
19	Investigation of the Prognostic Role of Carbonic Anhydrase 9 (CAIX) of the Cellular mRNA/Protein Level or Soluble CAIX Protein in Patients with Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2019, 20, 375.	4.1	20
20	S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Followâ€up. JDDG - Journal of the German Society of Dermatology, 2019, 17, 214-230.	0.8	57
21	S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 1: Epidemiology, Genetics and Diagnosis. JDDG - Journal of the German Society of Dermatology, 2019, 17, 94-103.	0.8	44
22	Synthesis and biological investigation of new carbonic anhydrase IX (CAIX) inhibitors. Chemico-Biological Interactions, 2018, 284, 12-23.	4.0	21
23	Factors Influencing Global Health Related Quality of Life in Elderly Cancer Patients: Results of a Secondary Data Analysis. Geriatrics (Switzerland), 2018, 3, 5.	1.7	7
24	Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) – Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities. Geburtshilfe Und Frauenheilkunde,	1.8	30
25	2018, 78, 1089-1109. Low HIF-11± and low EGFR mRNA Expression Significantly Associate with Poor Survival in Soft Tissue Sarcoma Patients; the Proteins React Differently. International Journal of Molecular Sciences, 2018, 19, 3842.	4.1	8
26	Number of radiotherapy treatment machines in the population and cancer mortality: an ecological study. Clinical Epidemiology, 2018, Volume 10, 1249-1273.	3.0	6
27	Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study. Geburtshilfe Und Frauenheilkunde, 2018, 78, 923-926.	1.8	9
28	Normoxic accumulation of HIF1Î $\pm$ is associated with glutaminolysis. Clinical Oral Investigations, 2017, 21, 211-224.	3.0	27
29	Trans sectoral care of geriatric cancer patients based on comprehensive geriatric assessment and patient-reported quality of life - Results of a multicenter study to develop and pilot test a patient-centered interdisciplinary care concept for geriatric oncology patients (PIVOG). Journal of Geriatric Oncology, 2017, 8, 262-270.	1.0	20
30	Analysis of health-related quality of life in patients with brain tumors prior and subsequent to radiotherapy. Oncology Letters, 2017, 14, 1841-1846.	1.8	24
31	Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer. BMC Cancer, 2017, 17, 6.	2.6	4
32	P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients. Clinical and Translational Radiation Oncology, 2017, 5, 6-11.	1.7	21
33	Dynamics of Heat Shock Protein 70 Serum Levels As a Predictor of Clinical Response in Non-Small-Cell Lung Cancer and Correlation with the Hypoxia-Related Marker Osteopontin. Frontiers in Immunology, 2017, 8, 1305.	4.8	35
34	The Impact of Non-Lethal Single-Dose Radiation on Tumor Invasion and Cytoskeletal Properties. International Journal of Molecular Sciences, 2017, 18, 2001.	4.1	12
35	Dosimetric comparison of intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) in total scalp irradiation: a single institutional experience. Radiation Oncology Journal, 2016, 34, 313-321.	1.5	26
36	The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer. Oncology Letters, 2016, 12, 3449-3456.	1.8	12

DIRK VORDERMARK

#	Article	IF	CITATIONS
37	Toward Restored Bowel Health in Rectal Cancer Survivors. Seminars in Radiation Oncology, 2016, 26, 236-250.	2.2	15
38	Coronary Heart Disease After Mediastinal Radiotherapy for Hodgkin Lymphoma: Can Risk Calculations From Historic Cohorts Be Used Today?. Journal of Clinical Oncology, 2016, 34, 2939-2940.	1.6	1
39	PRO-ONKO—selection of patient-reported outcome assessments for the clinical use in cancer patients—a mixed-method multicenter cross-sectional exploratory study. Supportive Care in Cancer, 2016, 24, 2503-2512.	2.2	11
40	Radiotherapy of brain metastases from breast cancer: Treatment results and prognostic factors. Oncology Letters, 2016, 11, 3223-3227.	1.8	11
41	Radiotherapy of Cervical Cancer. Oncology Research and Treatment, 2016, 39, 516-520.	1.2	43
42	Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines. Radiation Oncology, 2015, 10, 167.	2.7	12
43	Trans-sectoral care in patients with colorectal cancer: Protocol ofÂthe randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN). BMC Cancer, 2015, 15, 997.	2.6	6
44	Betulinyl Sulfamates as Anticancer Agents and Radiosensitizers in Human Breast Cancer Cells. International Journal of Molecular Sciences, 2015, 16, 26249-26262.	4.1	22
45	Correlation of Hsp70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer. Frontiers in Immunology, 2015, 6, 556.	4.8	67
46	Malignant melanoma brain metastases: Treatment results and prognostic factors - a single-center retrospective study. International Journal of Oncology, 2015, 46, 2439-2448.	3.3	11
47	mRNA expression levels of hypoxia-induced and stem cell-associated genes in human glioblastoma. Oncology Reports, 2015, 33, 3155-3161.	2.6	23
48	Quality of life in very elderly radiotherapy patients: a prospective pilot study using the EORTC QLQ-ELD14 module. Supportive Care in Cancer, 2015, 23, 1883-1892.	2.2	11
49	Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1101-1107.	0.8	12
50	Targeting of EGFR and HER2 with therapeutic antibodies and siRNA. Strahlentherapie Und Onkologie, 2015, 191, 180-191.	2.0	22
51	IDH1R132H mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status. Radiotherapy and Oncology, 2015, 116, 381-387.	0.6	33
52	Betulinic Acid Derivatives NVX-207 and B10 for Treatment of Glioblastoma—An in Vitro Study of Cytotoxicity and Radiosensitization. International Journal of Molecular Sciences, 2014, 15, 19777-19790.	4.1	30
53	Cervical Cancer in Ethiopia: Survival of 1,059 Patients Who Received Oncologic Therapy. Oncologist, 2014, 19, 727-734.	3.7	60
54	Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients. Strahlentherapie Und Onkologie, 2014, 190, 912-918.	2.0	7

DIRK VORDERMARK

#	Article	IF	CITATIONS
55	Long-term results of radiotherapy in anaplastic thyroid cancer. Radiation Oncology, 2014, 9, 90.	2.7	40
56	Osteopontin and splice variant expression level in human malignant glioma: Radiobiologic effects and prognosis after radiotherapy. Radiotherapy and Oncology, 2013, 108, 535-540.	0.6	31
57	The real face of HIF1α in the tumor process. Cell Cycle, 2012, 11, 3932-3936.	2.6	31
58	Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases. BMC Cancer, 2012, 12, 283.	2.6	71
59	Ten years of progress in radiation oncology. BMC Cancer, 2011, 11, 503.	2.6	7
60	Increased betulinic acid induced cytotoxicity and radiosensitivity in glioma cells under hypoxic conditions. Radiation Oncology, 2011, 6, 111.	2.7	37
61	Cardiac Magnetic Resonance Imaging Findings in 20-year Survivors of Mediastinal Radiotherapy for Hodgkin's Disease. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1117-1123.	0.8	68
62	HIF- $1\hat{l}\pm$ inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer, 2010, 10, 605.	2.6	85
63	Hypoxia-specific targets in cancer therapy: role of splice variants. BMC Medicine, 2010, 8, 45.	5.5	12
64	Effects of osteopontin inhibition on radiosensitivityof MDA-MB-231 breast cancer cells. Radiation Oncology, 2010, 5, 82.	2.7	36
65	Effects of Radiotherapy for Brain Metastases on Quality of Life (QoL). Strahlentherapie Und Onkologie, 2009, 185, 190-197.	2.0	60
66	Prospective evaluation of quality of life after permanent prostate brachytherapy with I-125: Importance of baseline symptoms and of prostate-V150. Radiotherapy and Oncology, 2009, 91, 217-224.	0.6	17
67	Immunohistochemical Detection of HIF-1α and CAIX in Advanced Head-and-Neck Cancer. Strahlentherapie Und Onkologie, 2008, 184, 393-399.	2.0	38
68	Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1α in human glioma in vitro and in vivo. Radiotherapy and Oncology, 2007, 83, 398-405.	0.6	90
69	Patterns of Care in the Radiotherapy of Prostate Cancer in Northern Bavaria 1998–2000. Strahlentherapie Und Onkologie, 2007, 183, 314-320.	2.0	9
70	Local control in 118 consecutive high-risk breast cancer patients treated with breast-conserving therapy. Oncology Reports, 2007, 18, 1335-9.	2.6	4
71	3-D reconstruction of anterior mantle-field techniques in Hodgkin's disease survivors: doses to cardiac structures. Radiation Oncology, 2006, 1, 10.	2.7	14
72	Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: Prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-11±-related markers, and hemoglobin levels. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1481-1487.	0.8	55

DIRK VORDERMARK

#	Article	IF	CITATIONS
73	Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer, 2006, 6, 207.	2.6	56
74	Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC Cancer, 2006, 6, 247.	2.6	36
75	3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: A cross-sectional quality-of-life survey. Acta Oncológica, 2006, 45, 708-716.	1.8	22
76	Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1197-1207.	0.8	73
77	Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer, 2005, 5, 55.	2.6	142
78	Glucose requirement for hypoxic accumulation of hypoxia-inducible factor-1α (HIF-1α). Cancer Letters, 2005, 230, 122-133.	7.2	65
79	Cell type–specific association of hypoxia-inducible factor-1α (HIF-1α) protein accumulation and radiobiologic tumor hypoxia. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1242-1250.	0.8	43
80	Endogenous Markers of Tumor Hypoxia. Strahlentherapie Und Onkologie, 2003, 179, 801-811.	2.0	125
81	Association of anorectal dose–volume histograms and impaired fecal continence after 3D conformal radiotherapy for carcinoma of the prostate. Radiotherapy and Oncology, 2003, 69, 209-214.	0.6	54
82	Chronic fatigue after radiotherapy for carcinoma of the prostate: correlation with anorectal and genitourinary function. Radiotherapy and Oncology, 2002, 62, 293-297.	0.6	23
83	Impaired Sphincter Function and Good Quality of Life in Anal Carcinoma Patients after Radiotherapy: A Paradox?. , 2001, 37, 132-139.		14
84	Brachytherapy. Cancer, 2001, 91, 1185-1186.	4.1	12
85	Curative-intent radiation therapy in anal carcinoma: quality of life and sphincter function. Radiotherapy and Oncology, 1999, 52, 239-243.	0.6	93